Cashu Markets
Cashu
Markets
  • Terminal
  • Stocks
  • Spotlight
  • News
Log inSign Up
  1. Stocks
  2. Healthcare
  3. NASDAQ
  4. DXCM

Market Cap: $33.87B

DI

DexCom, Inc.

DXCM
NASDAQ (NASDAQ Global Select)USD
Purchase DXCM
OverviewNewsAnalyst ReportsFinancialsPolitician TradesInsider TradesExecutivePatentsEarnings Surprise
Cashu Markets
Cashu
Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

Company

StocksAbout Cashu MarketsBrokersContact

Legal

Terms of ServicePrivacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

$89.75
USD
1.73(-1.89%)
At close: Aug 15, 11:26 EDT

Open

$71.30

Prev. Close

$91.48

High

$71.96

Low

$69.74

Company Profile

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

CEOJacob Steven Leach
SectorHealthcare

Recently from Cashu

Dexcom Enhances Diabetes Management with Redesigned Stelo App and Pediatric Biosensor Expansion

Dexcom Enhances Diabetes Management with Redesigned Stelo App and Pediatric Biosensor Expansion

Dexcom (Ticker: DXCM) is actively working to enhance diabetes management tools, with a focus on the newly redesigned Stelo app that will launch in July. This initiative aims to provide users with more…

Cashu Markets·2 months ago
Dexcom Launches FDA-Approved Stelo Glucose Monitor for Young Users Despite Stock Decline

Dexcom Launches FDA-Approved Stelo Glucose Monitor for Young Users Despite Stock Decline

Dexcom (Ticker: DXCM) embarks on a major expansion of its continuous glucose monitoring technology with the recent approval of its Stelo Glucose Biosensor System by the U.S. Food and Drug Administrati…

Cashu Markets·2 months ago
Dexcom Advances Pediatric Diabetes Care with Stelo's OTC FDA Approval for Continuous Glucose Monitoring

Dexcom Advances Pediatric Diabetes Care with Stelo's OTC FDA Approval for Continuous Glucose Monitoring

In a significant advancement for diabetes management among children, Dexcom (Ticker: DXCM) continues to solidify its role in the continuous glucose monitoring (CGM) space. The recent FDA approval of S…

Cashu Markets·2 months ago
Dexcom's G7 CGM Innovates Diabetes Management, Promises Improved Care for Type 2 Patients

Dexcom's G7 CGM Innovates Diabetes Management, Promises Improved Care for Type 2 Patients

Dexcom (Ticker: DXCM) announces significant developments in diabetes management at the American Diabetes Association’s Scientific Sessions. The company unveils promising results from its CONNECT trial…

Cashu Markets·2 months ago
IndustryMedical - Devices
Employees11.1K
IPO DateApr 14, 2005
ExchangeNASDAQ
Exchange NameNASDAQ Global Select
CurrencyUSD
Headquarters & Contact
Address6340 Sequence Drive
City / State / ZIPSan Diego, CA, 92121
CountryUnited States
Phone858 200 0200
Websitehttps://www.dexcom.com